Metabolomics in rheumatic diseases: The potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy

Autoimmunity Reviews

Volumn 12, Issue 10, 2013, Pages 1022-1030

  Priori, Roberta ^a   Scrivo, Rossana ^a   Brandt, Jessica ^b   Valerio, Mariacristina ^a   Casadei, Luca ^a   Valesini, Guido ^a   Manetti, Cesare ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Metabolomics; Osteoarthritis; Rheumatoid arthritis; Spondyloarthritis; Systemic lupus erythematosus

Indexed keywords

ALANINE; ASPARAGINE; BIOLOGICAL MARKER; CARNITINE; COLECALCIFEROL; FRUCTOSE; GLUCOSE; GLYCERIC ACID; GLYCEROL; GLYCINE; GLYCOLIC ACID; GLYOXYLIC ACID; HIGH DENSITY LIPOPROTEIN; HISTIDINE; HYPOXANTHINE; INOSITOL; ISOLEUCINE; LACTIC ACID; LEUCINE; LIPOPROTEIN A; METHOTREXATE; PHOSPHATE; PHOSPHATIDYLCHOLINE; PROLINE; PROPIONIC ACID; SORBITOL; TRYPTOPHAN; TYROSINE; URACIL;

DISEASE ACTIVITY; GAS CHROMATOGRAPHY; GENOMICS; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PROGNOSIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTOMICS;

BIOMARKERS; METABOLOMICS; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; METABOLOMICS; PROGNOSIS; PROTEOMICS; RHEUMATIC DISEASES;

EID: 84880584339     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.04.002     Document Type: Review

References (56)

1. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008, 455:1054-1056.
2. Holmes E., Wilson I.D., Nicholson J.K. Metabolic phenotyping in health and disease. Cell 2008, 134:714-717.
3. Heather L.C., Wang X., West J.A., Griffin J.L. A practical guide to metabolomic profiling as a discovery tool for human heart disease. J Mol Cell Cardiol 2013, 55:2-11.
4. Fernie A.R., Trethewey R.N., Krotzky A.J., Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol 2004, 5:763-769.
5. Trygg J., Holmes E., Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007, 6:469-479.
6. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007, 26:51-78.
7. Shushan B. A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. Mass Spectrom Rev 2010, 29:930-944.
8. Nicholson J.K., Holmes E., Kinross J.M., Darzi A.W., Takats Z., Lindon J.C. Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491:384-392.
9. Goodacre R., Broadhurst D., Smilde A.K., Kristal B.S., Baker J.D., Beger R., et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 2007, 3:231-241.
10. Smolinska A., Blanchet L., Buydens L.M.C., Wijmenga S.S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal Chim Acta 2012, 750:82-97.
11. Blandino G., Valerio M., Cioce M., Mori F., Casadei L., Pulito C., et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 2012, 3:865.
12. Li X., Yang S., Qiu Y., Zhao T., Chen T., Su M., et al. Urinary metabolomics as a potentially novel diagnostic and stratification tool for knee osteoarthritis. Metabolomics 2010, 6:109-118.
13. Ryan D., Robards K., Prenzler P.D., Kendall M. Recent and potential developments in the analysis of urine: a review. Anal Chim Acta 2011, 684:8-20.
14. Young S.P., Nessim M., Falciani F., Trevino V., Banerjee S.P., Scott R.A., et al. Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease. Mol Vis 2009, 15:1210-1217.
15. 1H NMR-based metabonomics. Nat Med 2002, 8:1439-1444.
16. Lin H.M., Helsby N.A., Rowan D.D., Ferguson L.R. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:1021-1029.
17. Ippolito J.E., Xu J., Jain S., Moulder K., Mennerick S., Crowley J.R., et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci U S A 2005, 102:9901-9906.
18. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
19. Seeger K. Metabolic changes in autoimmune diseases. Curr Drug Discov Technol 2009, 6:256-261.
20. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58:139-147.
21. Yi L.Z., Yuan D.L., Che Z.H., Liang Y.Z., Zhou Z.G., Gao H.Y., et al. Plasma fatty acid metabolic profile coupled with uncorrelated linear discriminant analysis to diagnose and biomarker screening of type 2 diabetes and type 2 diabetic coronary heart diseases. Metabolomics 2008, 4:30-38.
22. Holmes E., Loo R.L., Stamler J., Bictash M., Yap I.K., Chan Q., et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453:396-400.
23. Scott D.L., Wolfe F., Huizinga T.W.J. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
24. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
25. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012, 12:318-322.
26. Miossec P., Verweij C.L., Klareskog L., Pitzalis C., Barton A., Lekkerkerker F., et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011, 70:1713-1718.
27. Atzeni F., Antivalle M., Pallavicini F.B., Caporali R., Bazzani C., Gorla R., et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:431-437.
28. Weljie A.M., Dowlatabadi R., Miller B.J., Vogel H.J., Jirik F.R. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 2007, 9:3456-3464.
29. Smoleńska Z., Kaznowska Z., Zarówny D., Simmonds H.A., Smoleński R.T. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology 1999, 38:997-1002.
30. Rantapää-Dahlqvist S., Wallberg-Jonsson S., Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991, 50:366-368.
31. Giera M., Ioan-Facsinay A., Toes R., Gao F., Dalli J., Deelder A.M., et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta 1821, 2012:1415-1424.
32. van Wietmarshchen H.A., Dai W., van der Kooij A.J., Reijmers T.H., Schroen Y., Wang M., et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS ONE 2012, 7:e44331.
33. Jiang M., Xiao C., Chen G., Lu C., Zha Q., Yan X., et al. Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis. Front Med 2011, 5:219-228.
34. Gu Y., Lu C., Zha Q., Kong H., Lu X., Lu A., et al. Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Mol Biosyst 2012, 8:1535-1543.
35. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res 2010, 9:4545-4553.
36. Wang Z., Chen Z., Yang S., Wang Y., Yu L., Zhang B., et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. Exp Ther Med 2012, 4:165-171.
37. Madsen R.K., Lundstedt T., Gabrielsson J., Sennbro C.J., Alenius G.M., Moritz T., et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther 2011, 13(1):R19.
38. Meshitsuka S., Yamazaki E., Inoue M., Hagino H., Teshima R., Yamamoto K. Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Clin Chim Acta 1999, 281:163-167.
39. Braun J., Sieper J. Ankylosing spondylitis. Lancet 2007, 369:1379-1390.
40. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
41. Mau W., Zeidler H., Mau R., Majewski A., Freyschmidt J., Stangel W., et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988, 15:1109-1114.
42. Feldtkeller E., Khan M.A., van der Heijde D., van der Linden S., Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23:61-66.
43. Rudwaleit M., Khan M.A., Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005, 52:1000-1008.
44. Rudwaleit M., van der Heijde D., Landewe R., Listing J., Akkoc N., Brandt J., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
45. Robinson P.C., Wordsworth B.P., Reveille J.D., Brown M.A. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis 2013, 72:162-164.
46. Fischer R., Trudgian D.C., Wright C., Thomas G., Bradbury L.A., Brown M.A., et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol Cell Proteomics 2012, 11. [M111.013904].
47. Gao P., Lu C., Zhang F., Sang P., Yang D., Li X., et al. Integrated GC-MS and LC-MS plasma metabonomics analysis of ankylosing spondylitis. Analyst 2008, 133:1214-1220.
48. Wallace D., Hahn B.H. Dubois' Lupus Erythematosus and Related Syndromes 2013, Sanders Elsevier, Philadelphia. 8th ed.
49. 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. Lupus 2011, 20:1411-1420.
50. Blanco F.J., Ruiz-Romero C. Osteoarthritis: Metabolomic characterization of metabolic phenotypes in OA. Nat Rev Rheumatol 2012, 8:130-132.
51. Adams S.B., Setton L.A., Kensicki E., Bolognesi M.P., Toth A.P., Nettles D.L. Global metabolic profiling of human osteoarthritic synovium. Osteoarthritis Cartilage 2012, 20:64-67.
52. Zhai G., Wang-Sattler R., Hart D.J., Arden N.K., Hakim A.J., Illig T., et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann Rheum Dis 2010, 69:1227-1231.
53. Serkova N.J., Standiford T.J., Stringer K.A. The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med 2011, 184:647-655.
54. Hugle T., Kovacs H., Heijnen I.A., Daikeler T., Baisch U., Hicks J.M., et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol 2012, 30:240-245.
55. Jenkins M., Flynn A., Smart T., Harbron C., Sabin T., Ratnayake J., et al. PSI Biomarker Special Interest Group. A statistician's perspective on biomarkers in drug development. Pharm Stat 2011, 10:494-507.
56. Ellis D.I., Dunn W.B., Griffin J.L., Allwood J.W., Goodacre R. Metabolic fingerprint as a diagnostic tool. Pharmacogenomics 2007, 8:1243-1266.